Hepatitis Monthly

Published by: Kowsar

Resveratrol: Is It Really Good for Liver Health?

Sabine Weiskirchen 1 and Ralf Weiskirchen 1 , *
Authors Information
1 Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, Aachen, Germany
Article information
  • Hepatitis Monthly: August 2017, 17 (8); e12074
  • Published Online: August 4, 2017
  • Article Type: Review Article
  • Received: March 3, 2017
  • Revised: April 24, 2017
  • Accepted: August 28, 2017
  • DOI: 10.5812/hepatmon.12074

To Cite: Weiskirchen S, Weiskirchen R. Resveratrol: Is It Really Good for Liver Health?, Hepat Mon. 2017 ;17(8):e12074. doi: 10.5812/hepatmon.12074.

Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Context
2. Objectives
3. Evidence Acquisition
4. Results
5. Conclusions
  • 1. Takaoka M. The Phenolic Substances of White Hellebore (Veratrum Grandiflorum Hoes. Fil.) I. Nippon Kagaku Kaishi. 1939; 60(11): 1090-100[DOI]
  • 2. Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? Adv Nutr. 2016; 7(4): 706-18[DOI][PubMed]
  • 3. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425(6954): 191-6[DOI][PubMed]
  • 4. Murcia MA, Martinez-Tome M. Antioxidant activity of resveratrol compared with common food additives. J Food Prot. 2001; 64(3): 379-84[PubMed]
  • 5. Richard JL, Cambien F, Ducimetiere P. [Epidemiologic characteristics of coronary disease in France]. Nouv Presse Med. 1981; 10(14): 1111-4[PubMed]
  • 6. Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon JM. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci. 1997; 61(21): 2103-10[PubMed]
  • 7. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology. 2008; 47(6): 1947-54[DOI][PubMed]
  • 8. Rose AS, Hildebrand PW. NGL Viewer: a web application for molecular visualization. Nucleic Acids Res. 2015; 43-9[DOI][PubMed]
  • 9. Lee ES, Shin MO, Yoon S, Moon JO. Resveratrol inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Arch Pharm Res. 2010; 33(6): 925-32[DOI][PubMed]
  • 10. Hong SW, Jung KH, Zheng HM, Lee HS, Suh JK, Park IS, et al. The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Res. 2010; 33(4): 601-9[DOI][PubMed]
  • 11. Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M, et al. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res. 2010; 27(6): 1080-91[DOI][PubMed]
  • 12. Chan CC, Lee KC, Huang YH, Chou CK, Lin HC, Lee FY. Regulation by resveratrol of the cellular factors mediating liver damage and regeneration after acute toxic liver injury. J Gastroenterol Hepatol. 2014; 29(3): 603-13[DOI][PubMed]
  • 13. Vitaglione P, Ottanelli B, Milani S, Morisco F, Caporaso N, Fogliano V. Dietary trans-resveratrol bioavailability and effect on CCl4-induced liver lipid peroxidation. J Gastroenterol Hepatol. 2009; 24(4): 618-22[DOI][PubMed]
  • 14. Wojnarova L, Kutinova Canova N, Farghali H, Kucera T. Sirtuin 1 modulation in rat model of acetaminophen-induced hepatotoxicity. Physiol Res. 2015; 64 Suppl 4-87[PubMed]
  • 15. Du K, McGill MR, Xie Y, Bajt ML, Jaeschke H. Resveratrol prevents protein nitration and release of endonucleases from mitochondria during acetaminophen hepatotoxicity. Food Chem Toxicol. 2015; 81: 62-70[DOI][PubMed]
  • 16. Chen Z, Hu L, Lu M, Shen Z. Resveratrol reduces matrix metalloproteinases and alleviates intrahepatic cholestasis of pregnancy in rats. Can J Physiol Pharmacol. 2016; 94(4): 402-7[DOI][PubMed]
  • 17. Vega CC, Reyes-Castro LA, Rodriguez-Gonzalez GL, Bautista CJ, Vazquez-Martinez M, Larrea F, et al. Resveratrol partially prevents oxidative stress and metabolic dysfunction in pregnant rats fed a low protein diet and their offspring. J Physiol. 2016; 594(5): 1483-99[DOI][PubMed]
  • 18. Das SK, DesAulniers J, Dyck JR, Kassiri Z, Oudit GY. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload. Liver Int. 2016; 36(2): 246-57[DOI][PubMed]
  • 19. Salado C, Olaso E, Gallot N, Valcarcel M, Egilegor E, Mendoza L, et al. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med. 2011; 9: 59[DOI][PubMed]
  • 20. Zhang DQ, Sun P, Jin Q, Li X, Zhang Y, Zhang YJ, et al. Resveratrol Regulates Activated Hepatic Stellate Cells by Modulating NF-kappaB and the PI3K/Akt Signaling Pathway. J Food Sci. 2016; 81(1)-5[DOI][PubMed]
  • 21. Zhang H, Li Y, Su W, Ying Z, Zhou L, Zhang L, et al. Resveratrol attenuates mitochondrial dysfunction in the liver of intrauterine growth retarded suckling piglets by improving mitochondrial biogenesis and redox status. Mol Nutr Food Res. 2017; 61(5)[DOI][PubMed]
  • 22. Ahmad A, Ahmad R. Resveratrol mitigate structural changes and hepatic stellate cell activation in N'-nitrosodimethylamine-induced liver fibrosis via restraining oxidative damage. Chem Biol Interact. 2014; 221: 1-12[DOI][PubMed]
  • 23. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol. 2008; 295(4)-42[DOI][PubMed]
  • 24. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci. 2007; 80(11): 1033-9[DOI][PubMed]
  • 25. Das A. Heat stress-induced hepatotoxicity and its prevention by resveratrol in rats. Toxicol Mech Methods. 2011; 21(5): 393-9[DOI][PubMed]
  • 26. Tung BT, Rodriguez-Bies E, Talero E, Gamero-Estevez E, Motilva V, Navas P, et al. Anti-inflammatory effect of resveratrol in old mice liver. Exp Gerontol. 2015; 64: 1-7[DOI][PubMed]
  • 27. Hassan-Khabbar S, Vamy M, Cottart CH, Wendum D, Vibert F, Savouret JF, et al. Protective effect of post-ischemic treatment with trans-resveratrol on cytokine production and neutrophil recruitment by rat liver. Biochimie. 2010; 92(4): 405-10[DOI][PubMed]
  • 28. Ji G, Wang Y, Deng Y, Li X, Jiang Z. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. Lipids Health Dis. 2015; 14: 134[DOI][PubMed]
  • 29. Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L, et al. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res. 2015; 59(8): 1443-57[DOI][PubMed]
  • 30. Andrade JM, Paraiso AF, de Oliveira MV, Martins AM, Neto JF, Guimaraes AL, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014; 30(7-8): 915-9[DOI][PubMed]
  • 31. Abd El-Haleim EA, Bahgat AK, Saleh S. Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression. World J Gastroenterol. 2016; 22(10): 2931-48[DOI][PubMed]
  • 32. Pan QR, Ren YL, Liu WX, Hu YJ, Zheng JS, Xu Y, et al. Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats. Nutr Res. 2015; 35(7): 576-84[DOI][PubMed]
  • 33. Kozuki Y, Miura Y, Yagasaki K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett. 2001; 167(2): 151-6[PubMed]
  • 34. Kuo PL, Chiang LC, Lin CC. Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci. 2002; 72(1): 23-34[PubMed]
  • 35. Liu HS, Pan CE, Yang W, Liu XM. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol. 2003; 9(7): 1474-6[PubMed]
  • 36. Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E, Castanas E. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta. 2006; 1760(11): 1657-66[DOI][PubMed]
  • 37. Parekh P, Motiwale L, Naik N, Rao KV. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol. 2011; 63(1-2): 167-73[DOI][PubMed]
  • 38. Rajasekaran D, Elavarasan J, Sivalingam M, Ganapathy E, Kumar A, Kalpana K, et al. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Mol Med Rep. 2011; 4(6): 1211-7[DOI][PubMed]
  • 39. Dai W, Wang F, Lu J, Xia Y, He L, Chen K, et al. By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. Oncotarget. 2015; 6(15): 13703-17[DOI][PubMed]
  • 40. Nakamura M, Saito H, Ikeda M, Hokari R, Kato N, Hibi T, et al. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J Gastroenterol. 2010; 16(2): 184-92[PubMed]
  • 41. Jiang L, Gu Y, Ye J, Liu F, Zhao Y, Wang C, et al. Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein. Biotechnol Lett. 2012; 34(12): 2205-12[DOI][PubMed]
  • 42. Lee S, Yoon KD, Lee M, Cho Y, Choi G, Jang H, et al. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. Br J Pharmacol. 2016; 173(1): 191-211[DOI][PubMed]
  • 43. Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH, Tsai TF. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila). 2012; 5(7): 952-62[DOI][PubMed]
  • 44. Deng JJ, Kong KE, Gao WW, Tang HV, Chaudhary V, Cheng Y, et al. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochim Biophys Acta. 2017; 1860(4): 491-501[DOI][PubMed]
  • 45. Carafa V, Rotili D, Forgione M, Cuomo F, Serretiello E, Hailu GS, et al. Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics. 2016; 8: 61[DOI][PubMed]
  • 46. Cao D, Wang M, Qiu X, Liu D, Jiang H, Yang N, et al. Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev. 2015; 29(12): 1316-25[DOI][PubMed]
  • 47. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005; 280(17): 17038-45[DOI][PubMed]
  • 48. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des. 2009; 74(6): 619-24[DOI][PubMed]
  • 49. Sajish M, Schimmel P. A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature. 2015; 519(7543): 370-3[DOI][PubMed]
  • 50. Gledhill JR, Montgomery MG, Leslie AG, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci U S A. 2007; 104(34): 13632-7[DOI][PubMed]
  • 51. Davies DR, Mamat B, Magnusson OT, Christensen J, Haraldsson MH, Mishra R, et al. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem. 2009; 52(15): 4694-715[DOI][PubMed]
  • 52. Shukla PK, Gautam L, Sinha M, Kaur P, Sharma S, Singh TP. Structures and binding studies of the complexes of phospholipase A2 with five inhibitors. Biochim Biophys Acta. 2015; 1854(4): 269-77[DOI][PubMed]
  • 53. Nwachukwu JC, Srinivasan S, Bruno NE, Parent AA, Hughes TS, Pollock JA, et al. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. Elife. 2014; 3[DOI][PubMed]
  • 54. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011; 6(6)[DOI][PubMed]
  • 55. Vang O. What is new for resveratrol? Is a new set of recommendations necessary? Ann N Y Acad Sci. 2013; 1290: 1-11[DOI][PubMed]
  • 56. Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila). 2011; 4(9): 1419-25[DOI][PubMed]
  • 57. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011; 14(5): 612-22[DOI][PubMed]
  • 58. Dash S, Xiao C, Morgantini C, Szeto L, Lewis GF. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol. 2013; 33(12): 2895-901[DOI][PubMed]
  • 59. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012; 16(5): 658-64[DOI][PubMed]
  • 60. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014; 12(12): 2092-103 e1-6[DOI][PubMed]
  • 61. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014; 34(10): 837-43[DOI][PubMed]
  • 62. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015; 47(3): 226-32[DOI][PubMed]
  • 63. Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjaer Poulsen M, Stodkilde-Jorgensen H, Moller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016; 51(4): 456-64[DOI][PubMed]
  • 64. Elgebaly A, Radwan IA, AboElnas MM, Ibrahim HH, Eltoomy MF, Atta AA, et al. Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis. J Gastrointestin Liver Dis. 2017; 26(1): 59-67[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader